earnings
confidence high
sentiment positive
materiality 0.80
ADMA prelim FY2025 rev ~$510-511M, raises FY2026 rev/EBITDA guidance, targets >$1.1B by 2029
ADMA BIOLOGICS, INC.
2025-FY EPS reported
$0.60
revenue$510,173,000
- Preliminary FY2025 total revenue ~$510-511M, meeting or exceeding prior guidance. Cash grew to ~$88M with ~$40M Q4 operating cash flow.
- FY2026 revenue guidance raised to ~$635M (from $630M); FY2026 adjusted EBITDA raised to ~$360M (from $355M). Adjusted net income reiterated at ~$255M.
- FY2027 revenue guided ~$775M, adjusted net income ~$315M, adjusted EBITDA ~$455M.
- Long-term targets: >$1.1B revenue and >$700M adjusted EBITDA by FY2029. Yield-enhanced production now routine, 2026 first full year of monetization.
- Divested three plasma centers for $12M, secured long-term supply agreements, expects accretive cost savings from strategic repositioning.